PSYCHOPHARMACOLOGY, 2016: A MASTER CLASS
Offered by
Beth Israel Deaconess Medical Center
Department of Psychiatry
Friday and Saturday • April 1-2, 2016
The Fairmont Copley Plaza Hotel, Boston, MA

COURSE DIRECTORS
Carl Salzman, MD and Lawrence E. Lifson, MD

FACULTY
Ross Baldessarini, MD, DSc (hon)
Barbara Coffey, MD, MS
Jeffrey Lieberman, MD
Susan McElroy, MD
Charles Nemeroff, MD, PhD
John Ratey, MD
Carl Salzman, MD
Alan Schatzberg, MD
David Sheehan, MD, MBA
Stephen Stahl, MD, PhD
Roger Weiss, MD
John Winkelman, MD, PhD
Kimberly Yonkers, MD

• World renowned faculty
• Evidence based treatments
• Current and emerging treatments for schizophrenia and bipolar disorder
• Effective use of antidepressants
• Treatment resistant depression
• ADHD
• Psychopharmacologic treatment of anxiety spectrum and sleep disorders
• Interaction between psychiatric and medical illnesses
• Child, adolescent, and geriatric psychopharmacology
• Psychopharmacology of alcohol and substance abuse disorders
• Psychopharmacologic treatment of women’s mental health issues

Register early, this course has sold out each year that it has been given!

This program has no industry support.
This unique two-day course is designed for the experienced clinician. The objectives of this course are to provide, in a lecture and question and answer format, a review of the mechanisms and clinical applications of psychotropic drug treatments with particular emphasis on difficult-to-treat patients. Course participants will be expected to have had clinical experience, familiarity with the neurobiological and genetic contributions to psychiatric illnesses as well as an understanding of the basic therapeutic mechanisms of psychotropic medications. There will be considerable opportunity for interaction with the presenters.

LEARNING OBJECTIVES

Upon completion of this course, participants will be able to:

• Evaluate the effects of neurotransmitters and genes on psychotropic drug treatment;
• Describe the pharmacologic treatment of schizophrenia with particular reference to the prodromal period and first episode;
• Outline the emerging theories and treatments of bipolar disorder, depression, bipolar depression, stress and anxiety disorder;
• Describe the interaction between psychiatric and medical illnesses;
• Discuss the role of psychotropic medications in women's mental health with an emphasis on PMS, pregnancy, nursing, and the postpartum period;
• Review the appropriate use of medications in the treatment of sleep disorders;
• Review the appropriate use of stimulants in the treatment of attention and ADHD disorders as well as their use as an adjunct to antidepressant treatment;
• Assess the role of psychopharmacology in the treatment of substance use disorders with particular emphasis on alcohol, opiates, and cannabis;
• Describe the latest advances and problems associated with treatment approaches in the child, adolescent and geriatric populations.

This conference will focus on the following topics: An updated review of neurobiology and brain function will be presented, taking the attendee through neurotransmission sequence from neurotransmitter and synaptic function synthesis to gene transcription. The interaction between genes and the environment will be emphasized. The current use of antipsychotic drugs and mood stabilizing drugs for the treatment of schizophrenia and bipolar disorder will be presented; new antipsychotic medications will also be discussed along with potential new uses for mood stabilizers. A presentation will focus on the relationship between medical illness and psychiatric disorders with an emphasis on depression. A comprehensive review of the neurobiology and genetic predisposition to depression will be emphasized along with the modern use of antidepressants based on the latest research findings. There will be a presentation and focus on the diagnosis and treatment of attention deficit disorder with an emphasis on the use of stimulants in their treatment. The role of stimulants as adjunct to antidepressant treatment will be emphasized. Treatment of Bipolar Depression will be emphasized. The neurobiological mechanisms of anxiety and anxiety-spectrum disorders as well as their treatment will be presented, including obsessive-compulsive disorder, panic disorder, social anxiety disorder, PTSD, and generalized anxiety disorder. The neurobiological mechanisms of stress will also be emphasized. The importance of the evaluation and psychopharmacological treatment of women's mental health issues will be featured with particular emphasis on PMS, perinatal, and postpartum disorders. The course will also include a review of the role of psychopharmacology in the treatment of sleep disorders. Advances in the neurobiology and treatment of alcohol and substance abuse disorders will be highlighted. The latest advances in child, adolescent and geriatric psychopharmacology will be emphasized. Throughout the course the establishment and importance of the therapeutic alliance when prescribing all psychotropic medications will be underscored, as will the potential hazards/benefits of polypharmacy drug interactions.

PLANNING COMMITTEE
Carl Salzman, MD, Lawrence E. Lifson, MD, Elizabeth Kennedy, ANP-BC, & Daniel Brown, PhD

TARGET AUDIENCE
Experienced clinicians in the field of psychopharmacology drawn from the following disciplines: psychiatry, medicine, nursing, nurse practitioners, and psychology.

ACGME COMPETENCIES
This course is designed to meet one or more of the following Accreditation Council of Graduate Medical Education competencies:

• Practice-based Learning and Improvement
• Medical knowledge • Interpersonal and Communications Skills
Friday, April 1, 2016

7:45-8:15 am  Registration
8:15-8:20  Welcome and Overview
   Carl Salzman, MD
8:20-9:05  Implications of Neuroscience for Psychopharmacology: Neurons, Synapses, Circuits, Genes Enzymes
   Carl Salzman, MD
9:05-9:45  Rational Psychopharmacology: Treatment of Schizophrenia
   Jeffrey Lieberman, MD
9:45-10:30  The Curious Relationship Between Depression And Medical Disorders: Implications For Treatment
   Charles Nemeroff, MD, PhD
10:30-11:00  Coffee Break
11:00-11:45  Innovative Treatments of Resistant Psychiatric Disorders: Updated “Tricks of the Trade”
   Stephen Stahl, MD, PhD
11:45-12:00 pm  Panel Discussion and Q&A
   Carl Salzman, MD
   Jeffrey Lieberman, MD
   Charles Nemeroff, MD, PhD
   Stephen Stahl, MD, PhD
12:00-1:15  Lunch
1:15-2:00  Treatment of Bipolar Mania: The Role of Monotherapy and/or Polypharmacy
   Susan McElroy, MD
2:00-2:45  Advances in the Treatment of Bipolar Depression
   Ross Baldessarini, MD, DSc (hon)
2:45-3:00  Coffee Break
3:00-3:45  Progress in Treating Resistance Depression
   Alan Schatzberg, MD
3:45-4:30  Use of Stimulants for the Treatment of ADHD and Other Psychiatric Disorders
   John Ratey, MD
4:30-5:15  Panel Discussion and Q&A
   Susan McElroy, MD
   Ross Baldessarini, MD, DSc (hon)
   Alan Schatzberg, MD
   John Ratey, MD

Saturday, April 2, 2016

8:30-9:15 am  Rational use of Benzodiazepines and Antidepressants for Anxiety and Anxiety Spectrum Disorders
   David Sheehan, MD, MBA
9:15-10:00  Current State in the Diagnosis and Treatment of Sleep Disorder
   John Winkelman, MD, PhD
10:00-10:30  Coffee Break
10:30-11:15  Advances in the Treatment of Substance Abuse Disorders
   Roger Weiss, MD
11:15-12:00 pm  Panel Discussion and Q&A
   David Sheehan, MD, MBA
   John Winkelman, MD, PhD
   Roger Weiss, MD
12:00-1:15  Lunch
1:15-2:00  Therapeutic Uses of Psychotropic Drugs Across the Life Cycle of Women
   Kimberly Yonkers, MD
2:00-2:45  Child and Adolescent Psychopharmacology: Best Treatments
   Barbara Coffey, MD, MS
2:45-3:00  Coffee Break
3:00-3:45  Geriatric Psychopharmacology: Do Safety Concerns Compromise Therapeutic Benefits?
   Carl Salzman, MD
3:45-4:30  Panel Discussion and Q&A
   Kimberly Yonkers, MD
   Barbara Coffey, MD, MS
   Carl Salzman, MD
4:30  Adjourn

ACCREDITATION

Physicians: Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Harvard Medical School designates this live activity for a maximum of 13.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.

Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credit™ to an equivalent number of European CME Credits® (ECMECs®). Information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at: www.eaccme.eu.

Psychologists: The Continuing Education Program at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School is approved by the American Psychological Association to offer continuing education for psychologists.

The Continuing Education Program at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School maintains responsibility for the program.

Nurses: This activity has been submitted to the American Nurses Association Massachusetts for approval to award contact hours. The American Nurses Association Massachusetts is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Please call Stacy Ruiz at 617-754-1265 or e-mail sjruiz@bidmc.harvard.edu for more information about your credit hours.

Changes and substitutions may be made without notice.
Ross J. Baldessarini, MD, DSc. (hon) Professor of Psychiatry and in Neuroscience, Harvard Medical School; Director of the Psychopharmacology Program and International Consortium for Bipolar Disorder Research at McLean Hospital; Author of over 2100 scientific publications and several books, including Chemotherapy in Psychiatry and for several decades, the chapters on psychopharmacology in the standard American textbook of pharmacology, Goodman and Gilman’s The Pharmacological Basis of Therapeutics; Member of editorial boards of several leading clinical and neuroscience journals.

Barbara Coffey, MD, MS Professor of Psychiatry and Director of Residency Education in Child and Adolescent Psychiatry, Icahn School of Medicine at Mount Sinai; Professor, Department of Psychiatry and Research Psychiatrist, Nathan Kline Institute for Psychiatric Research; Associate Editor, Advanced Pediatric Psychopharmacology and Journal of Child and Adolescent Psychopharmacology.

Jeffrey Lieberman, MD Past president of American Psychiatric Association, Lawrence C. Kolb Professor and Chairman, Department of Psychiatry, Columbia University College of Physicians and Surgeons, Director, New York State Psychiatric Institute, Psychiatrist-in-Chief, Columbia University Medical Center of the NewYork-Presbyterian Hospital; Author of over 600 scientific articles and eleven books including Shrinks: The Untold Story of Psychiatry.

Lawrence E. Lifson, MD Lecturer on Psychiatry, Harvard Medical School; Director, Continuing Education Program, Department of Psychiatry, Beth Israel Deaconess Medical Center; Distinguished Life Fellow, American Psychiatric Association; Editor, Understanding Therapeutic Action: Current Concepts of Care and co-editor, Mental Health Practitioner and the Law and Psychology of Investing.

Susan L. McElroy, MD Professor of Psychiatry and Neuroscience, University of Cincinnati, College of Medicine; Chief Research Officer, Lindner Center of Hope, Author of over 125 scientific articles and books including Antiepileptic Drugs to Treat Psychiatric Disorders, Editorial board of 5 journals.

Charles Nemeroff, MD, PhD Leonard M. Miller Professor and Chairman, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine; past President of the American College of Psychiatrists, International Society of Psychoneuroendocrinology and the American College of Neuropsychopharmacology; member of the Institute of Medicine; author of over 1000 scientific articles and book chapters, Co-editor, Textbook of Psychopharmacology.

John Ratey, MD Associate Clinical Professor of Psychiatry, Harvard Medical School; Author of over 85 scientific publications and eight books including Driven to Distraction and The User’s Guide to the Brain and Spark: The New Revolutionary Science of Exercise and the Brain and Go Wild: Free Your Body and Mind From the Afflictions of Civilization.

Carl Salzman, MD Professor of Psychiatry, Harvard Medical School; Award-winning teacher of psychiatry and psychopharmacology; Editorial board or past editorial board of several journals including The American Journal of Psychiatry; Author of over 300 publications and several books including Clinical Geriatric Psychopharmacology, 4th edition.

Stephen M. Stahl, MD, PhD Professor of Psychiatry, University of California, San Diego; Honorary Visiting Senior Fellow, University of Cambridge, UK; recipient of many national and international awards; Author of over 500 publications; Author of 33 books including Essential Psychopharmacology and Prescriber’s Guide; Editor of 10 books; Editorial board of several journals including Editor-in-Chief, CNS Spectrums.

Alan F. Schatzberg, MD Kenneth Norris Jr. Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Emeritus, Stanford University; past President, American Psychiatric Association; Editorial board of many journals; Author of over 600 publications; Co-author, Manual of Clinical Psychopharmacology; Co-editor of Textbook of Psychopharmacology.

David Sheehan, MBA Distinguished University Health Professor at the University of South Florida College of Medicine, Director of the Depression and Anxiety Disorder Research Institute at the University of South Florida College of Medicine; past consultant to the World Health Organization and the U.S. Federal Drug Administration; Author of over 500 abstracts and 250 publications; Editorial board of 8 publications; author, The Anxiety Disease.

Roger Weiss, MD Professor of Psychiatry, Harvard Medical School and Chief of the Division of Alcohol and Drug Abuse at McLean Hospital. Author, over 300 scientific publications including, Integrated Group Therapy for Bipolar Disorder and Substance Abuse; Editorial board of many journals including American Journal of Drug and Alcohol Abuse, Journal of Clinical Psychiatry, and the American Journal on Addictions.

John Winkelman, MD, PhD Associate Professor of Psychiatry, Harvard Medical School; Past Chair of the Nosology committee of the American Academy of Sleep Medicine; Chair, Associate Editor of Sleep; Editorial boards of Sleep Medicine, CNS Drugs and the International Journal of Sleep Disorders; Editor, Foundations of Psychiatric Sleep Medicine.

Kimberly Yonkers, MD Professor in the Department of Psychiatry and Obstetrics, Gynecology and Reproductive Sciences at the Yale School of Medicine; past President of the North American Society of Psychosocial Ob-Gyn; Author, Depression in Women, and Co-editor of Mood Disorders in Women and Management of Psychiatric Disorders in Pregnancy.
REGISTRATION INFORMATION

Tuition Fee: Physicians and other Doctoral Level Registrants: $745. Nurses, Master Level Professional, Fellows, Residents and others: $545. *All fees shown in USD. Add processing fee (non-refundable) $5. Registration by credit card (VISA, MasterCard or American Express) or check can be made through Harvard Medical School’s secure online registration system at https://www.hmscmeregistration.org/psychopharmacology2016. Registration by check (draft on a United States bank), please make payable to Harvard Medical School. Phone or fax registration is not accepted. Registration with cash payment is not permitted. Upon receipt of your paid registration, you will receive an email confirmation. Be sure to include an email address that you check frequently. Your email address is used for critical information including registration confirmation, evaluation and certificate.

INQUIRIES
By phone 617-384-8600, Monday-Friday, 9 AM to 5 PM (EST) or by email at: ceprograms@hms.harvard.edu. For more information visit: www.cme.hms.harvard.edu or contact Stacy Ruiz (sjruiz@bidmc.harvard.edu) or 617-754-1265.

ONLINE INFORMATION
To register or view activity information online, visit: https://www.hmscmeregistration.org/psychopharmacology2016.

DISCLOSURE POLICY
Harvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS’s policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

REFUND POLICY
Refunds, less an administrative fee of $75, will be issued for all cancellations received two weeks prior to the start of the course. Refund requests must be received by postal mail, email, or fax. No refund will be issued should cancellation occur less than two weeks prior. “No shows” are subject to the full course fee and no refunds will be issued once the conference has started.

COURSE LOCATION
The Conference will be at the Fairmont Copley Plaza, 138 St. James Ave, Boston, MA. (Telephone: 617-267-5300)

ACCOMMODATIONS/TRAVEL
Hotel rooms in Boston are limited. You are urged to make your reservations early. A limited number of rooms have been reserved at the Fairmont Copley Plaza in Boston, MA for the sessions. Call 617-267-5300 or 800-441-1414 for reservations before March 29, 2016 for the discounted group rate. Please specify that you are with the Harvard Medical School Psychopharmacology course 2016 Psychopharmacology. https://resweb.passkey.com/go/psychopharmacology2016 Please do not purchase non-refundable airline ticket(s) until you have received an email from our office confirming your paid registration.
PSYCHOPHARMACOLOGY, 2016: A MASTER CLASS

Friday and Saturday • April 1-2, 2016

REGISTER ONLINE AT:
www.hmscmeregistration.org/psychopharmacology2016

COMMENTS FROM LAST YEAR’S CONFERENCE

“Best Psychopharmacology conference that I have been to.”

“Very applicable to daily practice. Good information challenging some common practice misconceptions”

“The speakers were internationally and nationally renowned”

“Honestly, the whole course was really, really exceptional!”